Alkylresorcinols (AR) are phenolic lipids present in the bran of whole grains, particularly in wheat and rye kernels. AR may serve as a biomarker of whole grain intake. While AR pharmacokinetics and principal end metabolites have been reported, the metabolic pathways contributing to their relatively rapid elimination from the circulation remain to be established. We investigated whether hepatic ω‐ and β‐oxidation mediate the catabolism of the AR homolog C19:0 to form 3,5‐dihydroxybenzoic acid and 3‐(3,5‐dihydroxyphenyl)‐1‐propanoic acid (DHPPA) using 3 in vitro platforms: human recombinant cytochrome P450 4F2 (CYP4F2), human liver S9 fraction (which includes microsomal and cytosolic enzymes), and HepG2 cells. After incubation with 10 μmol/L C19:0, one hydroxylated metabolite was formed by CYP4F2 and its production appeared to plateau after 1.0 h. After incubation of 10 μmol/L C19:0 with human S9 for up to 4 h, one hydroxylated and one carboxylated metabolite were identified, with their production increasing linearly with time. When HepG2 cells were treated with 5, 10, or 25 μmol/L C19:0 for 48 h, DHPPA was excreted into the media in a dose‐dependent manner. Our results are consistent with a metabolic pathway of absorbed AR to phenolic acids via CYP4F2‐mediated ω‐hydroxylation. Funded by the General Mills Inc. and USDA.